Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice

Alconada, 1996, A tyrosine-based motif and a casein kinase II phosphorylation site regulate the intracellular trafficking of the varicella-zoster virus glycoprotein I, a protein localized in the trans-Golgi network, Embo J., 15, 6096, 10.1002/j.1460-2075.1996.tb00998.x Babich, 2002, In vitro cytotoxicity of protocatechuic acid to cultured human cells from oral tissue: involvement in oxidative stress, Pharmacol. Toxicol., 91, 245, 10.1034/j.1600-0773.2002.910505.x Bresnahan, 1997, Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication, Virology, 231, 239, 10.1006/viro.1997.8489 Carpenter, 2009, Enumeration of an extremely high particle-to-PFU ratio for Varicella-zoster virus, J. Virol., 83, 6917, 10.1128/JVI.00081-09 Cohen, 2001, Varicella-zoster virus (VZV) ORF65 virion protein is dispensable for replication in cell culture and is phosphorylated by casein kinase II, but not by the VZV protein kinases, Virology, 280, 62, 10.1006/viro.2000.0741 Cohen, 2001, Varicella-zoster virus and its replication, vol.2, 2707 Corbel, 2009, Identification of potential cellular targets of aloisine A by affinity chromatography, Bioorg. Med. Chem., 17, 5572, 10.1016/j.bmc.2009.06.024 De Clercq, 2004, Antiviral drugs in current clinical use, J. Clin. Virol., 30, 115, 10.1016/j.jcv.2004.02.009 Diwan, 2004, Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors, J. Virol., 78, 9352, 10.1128/JVI.78.17.9352-9365.2004 Dothager, 2009, Advances in bioluminescence imaging of live animal models, Curr. Opin. Biotechnol., 20, 45, 10.1016/j.copbio.2009.01.007 Goga, 2007, Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC, Nat. Med., 13, 820, 10.1038/nm1606 Habran, 2005, Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity, J. Biol. Chem., 280, 29135, 10.1074/jbc.M503312200 Hay, 1977, The effect of phosphonoacetic acid on herpes viruses, J. Antimicrob. Chemother., 3, 63, 10.1093/jac/3.suppl_A.63 Holcomb, 2006, A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia, J. Drugs Dermatol., 5, 863 Huang, 1976, Preferential inhibition of herpes-group viruses by phosphonoacetic acid: effect on virus DNA synthesis and virus-induced DNA polymerase activity, Yale J. Biol. Med., 49, 93 Johnson, 2008, Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient, Drugs Aging, 25, 991, 10.2165/0002512-200825120-00002 Kabir, 2002, Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis, Biochem. J., 367, 145, 10.1042/bj20020665 Knockaert, 2000, Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors, Chem. Biol., 7, 411, 10.1016/S1074-5521(00)00124-1 Knockaert, 2002, p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol, Oncogene, 21, 6413, 10.1038/sj.onc.1205908 Kudoh, 2004, Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication, J. Virol., 78, 104, 10.1128/JVI.78.1.104-115.2004 Leisenfelder, 2006, Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity, J. Virol., 80, 5577, 10.1128/JVI.00163-06 Leisenfelder, 2008, Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions, J. Virol., 82, 12116, 10.1128/JVI.00153-08 Luker, 2002, Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice, J. Virol., 76, 12149, 10.1128/JVI.76.23.12149-12161.2002 Luker, 2008, Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation, Antiviral Res., 78, 179, 10.1016/j.antiviral.2008.01.158 Meggio, 1990, Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1, Eur. J. Biochem., 187, 89, 10.1111/j.1432-1033.1990.tb15280.x Meggio, 2003, One-thousand-and-one substrates of protein kinase CK2?, FASEB J., 17, 349, 10.1096/fj.02-0473rev Meijer, 2003, Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials, Acc. Chem. Res., 36, 417, 10.1021/ar0201198 Mettey, 2003, Aloisines, a new family of CDK/GSK-3 inhibitors, SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects, J. Med. Chem., 46, 222, 10.1021/jm020319p Moffat, 1995, Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice, J. Virol., 69, 5236, 10.1128/JVI.69.9.5236-5242.1995 Moffat, 1998, Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse, J. Virol., 72, 965, 10.1128/JVI.72.2.965-974.1998 Moffat, 1999, Varicella-zoster virus infection of T cells and skin in the SCID-hu mouse model, 973 Moffat, 2004, Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis, Biochim. Biophys. Acta, 1697, 225, 10.1016/j.bbapap.2003.11.026 Mueller, 2009, Phosphorylation of the nuclear form of varicella-zoster virus immediate-early protein 63 by casein kinase II at serine 186, J. Virol., 83, 12094, 10.1128/JVI.01526-09 Nagaike, 2004, Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli, Vaccine, 22, 4069, 10.1016/j.vaccine.2004.03.062 Niizuma, 2003, Construction of Varicella-zoster virus recombinants from parent oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model, J. Virol., 77, 6062, 10.1128/JVI.77.10.6062-6065.2003 Oliver, 2008, Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts, J. Virol. Methods, 154, 182, 10.1016/j.jviromet.2008.07.033 Pedrali-Noy, 1980, Mechanism of inhibition of herpes simplex virus and vaccinia virus DNA polymerases by aphidicolin, a highly specific inhibitor of DNA replication in eucaryotes, J. Virol., 36, 457, 10.1128/JVI.36.2.457-464.1980 Perry, 2005, Mimosine attenuates serine hydroxymethyltransferase transcription by chelating zinc. Implications for inhibition of DNA replication, J. Biol. Chem., 280, 396, 10.1074/jbc.M410467200 Pinna, 1997, Protein kinase CK2 (“casein kinase-2”) and its implication in cell division and proliferation, Prog. Cell Cycle Res., 3, 77, 10.1007/978-1-4615-5371-7_7 Prather, 1999, Cell cycle analysis of cultured porcine mammary cells, Cloning, 1, 17, 10.1089/15204559950020067 Raynaud, 2004, Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis, Mol. Cancer Ther., 3, 353, 10.1158/1535-7163.353.3.3 Reardon, 1989, Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate, J. Biol. Chem., 264, 7405, 10.1016/S0021-9258(18)83248-3 Renò, 1999, Mimosine induces apoptosis in the HL60 human tumor cell line, Apoptosis, 4, 469, 10.1023/A:1009608628076 Repetto, 2008, Neutral red uptake assay for the estimation of cell viability/cytotoxicity, Nat. Protoc., 3, 1125, 10.1038/nprot.2008.75 Sampathkumar, 2009, Herpes zoster (shingles) and postherpetic neuralgia, Mayo Clin. Proc., 84, 274, 10.4065/84.3.274 Sanchez, 2004, Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production, J. Virol., 78, 11219, 10.1128/JVI.78.20.11219-11232.2004 Schang, 2000, Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins, J. Virol., 74, 2107, 10.1128/JVI.74.5.2107-2120.2000 Schang, 2005, Cdk inhibitory nucleoside analogs prevent transcription from viral genomes, Nucleosides Nucleotides Nucleic Acids, 24, 829, 10.1081/NCN-200060314 Schang, 2006, First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy, Expert Rev. Anti Infect. Ther., 4, 953, 10.1586/14787210.4.6.953 Taylor, 2004, Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus, J. Virol., 78, 2853, 10.1128/JVI.78.6.2853-2862.2004 Taylor, 2005, Replication of varicella-zoster virus in human skin organ culture, J. Virol., 79, 11501, 10.1128/JVI.79.17.11501-11506.2005 Tischer, 2007, A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9, J. Virol., 81, 13200, 10.1128/JVI.01148-07 Vafai, 2001, Zoster in patients infected with HIV: a review, Am. J. Med. Sci., 321, 372, 10.1097/00000441-200106000-00003 Vázquez, 2004, Effectiveness over time of varicella vaccine, JAMA, 291, 851, 10.1001/jama.291.7.851 Verri, 1994, Aphidicolin inhibits in vitro the activity of pseudorabies virus (PRV) DNA polymerase and in vivo the viral proliferation, In Vivo, 8, 1041 Villerbu, 2002, Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities, Int. J. Cancer, 97, 761, 10.1002/ijc.10125 Wang, 2008, Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology, Trends Pharmacol. Sci., 29, 302, 10.1016/j.tips.2008.03.003 Wang, 2003, Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging, Blood, 102, 3478, 10.1182/blood-2003-05-1432 Yao, 1993, Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI, J. Virol., 67, 4464, 10.1128/JVI.67.8.4464-4473.1993 Ye, 1999, Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase, J. Virol., 73, 1320, 10.1128/JVI.73.2.1320-1330.1999 Yoshii, 2007, Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus, Vaccine, 25, 5006, 10.1016/j.vaccine.2007.04.064 Zapata, 2007, Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway, J. Virol., 81, 977, 10.1128/JVI.01470-06 Zeuzem, 2008, Interferon-based therapy for chronic hepatitis C: current and future perspectives, Nat. Clin. Pract. Gastroenterol. Hepatol., 5, 610, 10.1038/ncpgasthep1274 Zhang, 2007, Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system, J. Virol., 81, 9024, 10.1128/JVI.02666-06